Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Determine which funds deliver the best annual risk-adjusted returns and how they stack up. Compare contenders to pick winners.
28,456 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Lawmakers delay a major stablecoin bill, triggering renewed frustration across crypto traders as markets react to pol...
Dell shares tumbled about 14% as investors pulled back from AI hardware names, with HPE and Super Micro also sliding....
As HubSpot prepares to report its 2026 earnings, investors want clarity on growth drivers, profitability, and strateg...
Investors are watching Meta’s next moves as chatter around a cloud-scale partnership heats up. This piece explains wh...
Himax (HIMX) faces a pivotal year as AR/VR, automotive displays, and smartphone drivers shape demand. This Q1 2026 ea...
Delinquencies eased in March to 3.35%, though higher-severity stress remains elevated. FHA loans push delinquency sha...
POET Technologies posted a quarterly miss as a Lumilens deal slows and litigation casts a shadow over growth prospect...
QUBT surged alongside quantum peers on policy chatter, but the rally raises questions about fundamentals and governme...
When a CFO buys a sizable block of shares, it can hint at confidence in the company’s future. This article breaks dow...
A federally funded health study tied to the Biden administration finds no safe level of alcohol and warns risks rise ...
Bitcoin is testing a critical resistance near $70,000 as volatility persists. Analysts say a confirmed move above thi...